Can the Xpert MRSA/SA BC assay be used as an antimicrobial stewardship tool? A prospective assay validation and descriptive impact assessment study in a South African setting

Kessendri Reddy (kessendri@yahoo.com)
Stellenbosch University Faculty of Medicine and Health Sciences, National Health Laboratory Services
https://orcid.org/0000-0002-6701-9764

Andrew Christopher Whitelaw
Stellenbosch University Faculty of Medicine and Health Sciences

Research article

Keywords: Staphylococcus aureus, Xpert MRSA/SA BC, staphylococcal bloodstream infection, antimicrobial stewardship

DOI: https://doi.org/10.21203/rs.3.rs-42515/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background:

Positive blood cultures showing Gram positive cocci in clusters signifies either *Staphylococcus aureus* or the less-virulent coagulase-negative staphylococci. Rapid identification and methicillin susceptibility determination with the Xpert MRSA/SA BC assay can improve management of *S. aureus* bloodstream infection and reduce inappropriate antibiotic use.

Methods:

We prospectively evaluated the Xpert MRSA/SA BC assay in comparison with culture, on samples referred to our laboratory in the Western Cape, South Africa. We interviewed attending clinicians upon culture result availability, to assess antibiotic choices and estimate potential impact of the assay.

Results:

Of the 231 samples included, there was 100% concordance between the Xpert MRSA/SA BC assay and culture (methicillin-resistant *S. aureus* 15/15, methicillin-susceptible *S. aureus* 42/42, coagulase-negative staphylococci 170/170). Time to final result could be reduced by approximately 30 hours with the assay. Of the 178 patients with adequate antibiotic history, optimisation of antistaphylococcal therapy could have occurred more than one day sooner in 68.9% with *S. aureus* bloodstream infection (31/45, 95% CI 53.2-81.4%). Six of the 11 patients with methicillin-resistant *S. aureus* bloodstream infection (54.5%) could have received anti-MRSA cover sooner. Fifty-four days of antibiotic therapy could have been spared, equating to 0.3 days (95% CI, 0.2-0.4) saved per patient, driven by broad-spectrum beta-lactams (32 days, in 18.0% of the cohort).

Conclusion:

This assay has potential as an antimicrobial stewardship tool; costing and impact on clinical outcome in patients with *S. aureus* bloodstream infection should be assessed.

Background

*Staphylococcus aureus* is a common cause of bloodstream infection (BSI) (1), with a mortality rate of 20-40% (1). In contrast, coagulase-negative staphylococci (CoNS) are generally regarded as skin commensals of low pathogenic potential, although they can be clinically significant in selected circumstances.

Differentiating between CoNS and *S. aureus* in positive blood culture broths showing Gram positive cocci in clusters (GPCC) on Gram stain, typically requires assessment of morphological and biochemical characteristics after overnight incubation. In addition, susceptibility testing is required to differentiate between methicillin-susceptible and methicillin-resistant *S. aureus* (MSSA and MRSA, respectively). These
requirements can result in delayed initiation of appropriate therapy in patients with *S. aureus* BSI, with potentially adverse outcomes including secondary infectious complications (2), a higher mortality rate and prolonged hospital stay (1). Conversely, inappropriate antibiotic administration unnecessarily exposes the patient to potential adverse effects of the medication, alters gastrointestinal flora, and also has ecological effects, including contributing to antibiotic selective pressure which drives resistance.

The Xpert MRSA/SA BC System (Cepheid, Sunnyvale, California) differentiates between MRSA, MSSA and CoNS from positive blood cultures within approximately one hour, using a real-time, semi-automated, nucleic acid-based test which targets *spa* and the SCC*mec-orfX* junction (for *S. aureus*), and *mecA* (for methicillin resistance). Published studies, summarised in one paper (3), report sensitivities and specificities of 96.4-100% and 98.0-100%, respectively, for the detection of MSSA, and values of 87.5-100% and 98.3-100% respectively, for detection of MRSA. Initial concerns regarding undercalling of MRSA with specific SCC*mec* variants, were resolved in 2013 (3).

We evaluated the Xpert MRSA/SA BC System (Xpert) and assessed the potential impact of implementation of this test as an antimicrobial stewardship tool in the patient population served by our laboratory in Cape Town, South Africa.

**Methods**

**Study aims, design and setting**

We aimed to assess the performance and role of the Xpert in facilitating more appropriate antibiotic use in patients with *S. aureus* bloodstream infection, and reducing inappropriate antibiotic therapy in those with *S. aureus* and with coagulase-negative staphylococci. We performed a prospective observational study to evaluate the Xpert against the reference method of culture-based techniques, and to describe the potential impact of implementation of this assay in our setting by combining clinical history with attending clinician survey.

The study took place from January to June 2016 at the National Health Laboratory Service (NHLS) Microbiology laboratory at Tygerberg Hospital in the Western Cape, South Africa. Tygerberg Hospital is a 1384-bedded referral hospital serving the northern and eastern subdistricts of the Cape Metro region, and the surrounding rural districts, including 4 regional hospitals and 17 district hospitals.

Blood culture bottles were submitted from facilities throughout this drainage area, at the clinicians’ discretion. The automated blood culture system in use is the BacT/Alert 3D Microbial Identification System (bioMérieux, Marcy L’Étoile, France) which includes anaerobic (FN Plus), aerobic (FA Plus) and paediatric bottles (PF Plus). These were kept at room temperature during transport, and were incubated as soon as possible after specimen receipt. After flagging positive, Gram stains are performed on an aliquot of the broth. All patients with positive blood cultures exclusively showing GPCC on Gram stain, were included. Blood culture specimens showing mixed morphology on Gram stain, and duplicate blood culture samples from the same patient, were excluded.
Paediatric patients were defined as patients below the age of 13 years.

**Classification and management of suspected sepsis**

Patients with positive blood cultures (indicating suspected sepsis) were defined as having community-acquired (CA) infection if the culture was collected <72 hours after admission, and hospital acquired (HA) infection thereafter; admission within the preceding 6 weeks also considered as a criterion for HA infection (4).

Empiric management of CA infections was based on local guidelines, with ceftriaxone or amoxicillin-clavulanate used for most infections; cloxacillin was recommended where *S. aureus* was likely. During the study period, standard-of-care was to administer a carbapenem +/- vancomycin (for suspected MRSA) for presumed hospital-acquired sepsis.

Regional hospital guidelines in our drainage area advise a targeted approach of a semi-synthetic beta-lactamase stable penicillin (cloxacillin) for MSSA BSI, with vancomycin advised for MRSA BSI.

**Validation**

*Laboratory processing*

Consecutive samples were processed in parallel using culture-based methods and Xpert, during weekdays between 8am and 4pm. The investigator performing the Xpert was blinded to the culture results.

Culture-based methods entailed inoculation and overnight incubation of basic enriched agar media; Kirby-Bauer disk diffusion testing of an aliquot of broth against a standard anti-staphylococcal antibiotic panel; and identification using DNAse and Mannitol Salt Agar (MSA) plates. A rapid latex agglutination test was performed using the Pastorex Staph Plus kit (Bio-Rad, Hercules, California) for indeterminate identification results. VITEK 2 Gram positive ID confirmation (bioMérieux, Marcy L'Étoile, France) was used at the discretion of the clinical microbiologist, and methicillin susceptibility was determined by cefoxitin disk diffusion testing using the Clinical and Laboratory Standards Institute (CLSI) guidelines (5).

Batched Xpert testing was performed on blood culture bottles, which were stored at 35°C following culture-based processing. The Xpert MRSA/SA BC G3 version 5 (Cepheid, Sunnyvale, California) was performed as per manufacturer's instructions. Briefly, 50μl of blood culture broth was added to the vial containing the elution reagent and vortexed for 10 seconds. The contents of the vial were transferred to the test cartridge and loaded into the module. Xpert testing was performed as soon as possible after positivity; there was a maximum delay of 80 hours for bottles flagging positive over a weekend. The results of the Xpert assay were not made available to the clinicians.

The results of these methods were interpreted as summarised in Table 1.
As per standard practice, clinicians were contacted with the Gram stain result if the available clinical information or previous results suggested *S. aureus* sepsis, or if the patient was admitted in an Intensive Care Unit (ICU). In all other cases, clinicians were contacted with the culture result, whether *S. aureus* or CoNS.

Basic clinical and demographic information were obtained, including an antibiotic history. We surveyed the attending clinicians to assess whether knowledge of the culture and susceptibility result on the day the bottle flagged positive would have impacted antibiotic choice. This was categorised as:

- **Modification**: a change from an ineffective to a more effective agent, or the addition of a semisynthetic penicillin (MSSA) or glycopeptide (MRSA);
- **De-escalation**: a change in antibiotic to a narrower-spectrum, targeted antistaphylococcal agent, or cessation of some or all antibiotics;
- **No change**: no change to the empiric antibiotic regimen, or no antibiotics prescribed if the patient was not receiving antibiotics.

We regarded cephalosporins (with the exception of ceftazidime), beta-lactam–beta-lactamase inhibitors, carbapenems and vancomycin as being active against MSSA. Penicillin, ampicillin, amoxicillin, and ceftazidime were the beta-lactam agents regarded as being ineffective against MSSA.

CoNS were considered significant only if reported as the likely cause for the patient's clinical condition, as judged by the attending clinician.

Days of antibiotic therapy saved were also evaluated during clinician interview, based on the empiric antibiotic regimen commenced and on clinician opinion as to whether an earlier result would have impacted antibiotic choice or duration (i.e. if the Xpert had been utilised as soon as the bottle flagged positive, leading to a “final” result being available shortly after Gram stain availability).

**Statistical analysis**

Microsoft Excel, VassarStats (www.vassarstats.net) and EpiCalc 2000 v1.02 (Brixton Books, South London, UK) were used, with an α-level of 0.05 chosen. Continuous numerical variables were summarised using means and standard deviations for normally distributed variables, or medians and interquartile ranges (IQR) for variables not following a normal distribution. Binary categorical variables were summarised using proportions and 95% confidence intervals (CI). Comparison of selected independent proportions were evaluated using the z-test.

**Results**

Our laboratory processed 2822 positive blood culture bottles between January and June 2016. Of these, 1158 (41.0%, 95% CI 39.2-42.9%) demonstrated only GPCC on Gram stain and 231 samples were included in the study (19.9%, 95% CI 17.7-22.4%) due to convenience sampling. Selected variables were
compared between the participants included in the study and all patients for whom blood cultures were submitted showing Gram positive cocci in clusters on Gram stain, between January and June 2016. No differences in age, gender or ward location per organism type at blood culture sampling were noted, with the exception of a larger proportion of coagulase-negative staphylococci from patients admitted to surgical wards (15.9% vs 9.2%, p 0.006) and high care units/ICU (15.9% vs 8.3%, p 0.002) in the study population. Contribution of the bottle types is outlined in Table 2.

**Validation**

A valid Xpert result was initially obtained from 225/231 bottles (97.4%, 95% CI 94.5-98.8%). Of the remaining 6 assays, 2 (2.6%, 95% CI 1.2-5.6%) were invalid (failure of internal control) and were not repeated. Four were resulted as “error” with signal loss after initial amplification; two provided a valid result after repeat testing. The conservative failure rate was 1.7% (95% CI 0.7-4.4%), with 227 bottles yielding an interpretable result.

MSSA was present in 42 samples (18.5%, 95% CI 14.0-24.1%) and MRSA in 15 (6.6%, 95% CI 4.1-10.6%). CoNS were present as the sole isolate in 169 patients, and were part of mixed cultures in an additional 4 cases. Three of these 4 mixed cultures contained MSSA together with CoNS, were detected as MSSA by the Xpert, and were included as MSSA in the analysis. The fourth culture contained *Klebsiella pneumoniae* (Gram negative bacilli missed on Gram stain) and a CoNS; the Xpert correctly assessed the CoNS.

There was 100% concordance between the systems for the identification of MSSA, MRSA and CoNS. The Xpert assay had an overall sensitivity of 100% (57/57; 95% CI 93.7-100%), and specificity of 100% (170/170, 95% CI 97.8-100%). The positive and negative predictive values of the assay were both 100% (95% CIs 93.7-100% and 97.8-100% respectively). Analysis by MSSA, MRSA and CoNS is summarised in Supplementary Table 1.

We performed a subanalysis of *mecA* and methicillin resistance in CoNS, for the 169 isolates in which cefoxitin susceptibility on culture was known. The gene target, *mecA*, was detected in 85 of 88 CoNS isolates that were cefoxitin-resistant on culture (96.6%; 95% CI 90.5%-98.8%) giving a positive predictive value of 86.7% (95% CI 78.6-92.1%). The specificity of detection of *mecA* in CoNS on Xpert was 84.0% (95% CI 74.5-90.4%) with a negative predictive value of 95.8% (95% CI 88.3-98.6%).

**Potential impact of implementation**

The median time between blood culture positivity and final result authorisation was 31.3h (interquartile range [IQR] 20.7-42.5h).

Of the 227 patients included, 50.7% (115/227, 95% CI 44.0-57.3%) were males. The median age of the adults included was 43.0 years (IQR 31.0-58.0); the median age of the paediatric population was 71.5 days (IQR 17.8-325.0). Twenty-five adults (25/151, 16.6%, 95% CI 11.2-23.7%) and 10 children (10/76, 13.2%, 95% CI 6.8-23.3%) were admitted to an ICU at the time of blood culture collection. Sepsis was CA
in 51.1% (116/227, 95% CI 44.4-57.8%), HA in 38.3% (87/227, 95% CI 32.0-45.0%); and unknown in the remaining 10.6% (24/227, 95% CI 7.0-15.5%). Only 1/11 with MRSA BSI reportedly had CA onset of infection (9.1%, 95% CI 0.5-42.9%).

Adequate history regarding source of sepsis was obtained for 195 patients. Sixty-two patients (31.8%, 95% CI 25.4-38.9%) had an unclear source of sepsis. Respiratory tract infection was the most commonly identified suspected source overall (56/195, 28.7%, 95% CI 22.6-35.7%) and in CA-infection (33/101, 32.7%, 95% CI 23.9-42.8%). For HA-infection, 29 patients (36.3%, 95% CI 26.0-47.8%) had no clear source of sepsis; of those with known primary sources, the major foci were the respiratory tract and skin or skin structures (both 18/80 patients, 22.5%, 95% CI 14.2-33.5%).

Information on the suspected source of sepsis was obtained in 46 patients with *S. aureus* BSI. The most commonly identified suspected source of sepsis (in isolation or as part of two potential sources) was skin or skin structure infection (n=16, 34.8%), followed by suspected respiratory tract infection (n=11, 23.9%). Source was undetermined at the time of clinician interview in 8 patients with *S. aureus* BSI (17.4%).

Characteristics of the included patients can be found in Supplementary Table 2.

**Impact on antibiotic administration**

Adequate antibiotic history was obtained in 181 patients, including 34 with MSSA and 11 with MRSA BSI. Three patients were unclassified due to discordance between culture result, clinical history and antibiotic therapy; these were excluded from the analysis (additional notes in Supplementary Table 3). Empiric antibiotic therapy choices for the remaining 178 patients (including one with significant CoNS BSI resulting from a central line infection) are outlined in Figure 1.

The antibiotic changes over time are summarised in Figure 2 (whole cohort) and Table 3 (subgroup with *S. aureus* BSI). The impact of the Xpert could be discerned by proxy if culture result availability approximated availability of the Gram stain result (i.e. final result available about an hour after Gram stain availability, in place of the overnight incubation required by reference methods). Analysis by organism category (MRSA, MSSA or CoNS) can be found in Supplementary Table 4.

**MRSA**

Most patients with MRSA BSI did not receive an MRSA-active agent until release of the final culture result (Table 3). Cessation of an additional antimicrobial agent occurred in 7 patients on final culture result (63.6%, 95% CI 31.6-87.6%); this could have occurred at least one day sooner with Xpert.

**MSSA**

For the 34 patients who had MSSA BSI, notable aspects of the antibiotic regimen include:
• **Empiric cover**: Empiric vancomycin was prescribed unnecessarily in 3/34 (8.8%, 95% CI 2.3-24.8%); this could have been avoided if Xpert was used.

• **In response to Gram stain availability**: 2/34 (5.9%, 95% CI 1.0-21.1) received modifications to their antibiotic regimens in response to Gram stain result availability. In one case, vancomycin was started when the Gram stain became available. In the second, a non MSSA-active beta-lactam agent (ampicillin) was changed to an MSSA-active agent (cefotaxime).

• **In response to final culture result availability**: Overall, there was a change in antibiotic therapy on final result in 25 patients (73.5%, 95% CI 55.4-86.5%). These could have occurred at least one day earlier had the Xpert assay been used.
  1. **De-escalation** to a semisynthetic penicillin in 18/25 (72.0%, 95% CI 50.4-87.1%)
  2. **Modification** to a more effective agent in the remaining 7/25 (28.0%, 95% CI 12.9-49.6%)

**CoNS**

Antibiotics were stopped in 13/133 patients on release of the final result indicating CoNS (9.8%, 95% CI 5.5-16.5%).

**Antimicrobial stewardship impact**

Overall, 31/45 patients with *S. aureus* BSI and known antibiotic history could have received more appropriate antistaphylococcal therapy one day sooner, with adoption of the Xpert assay (68.9%, 95% CI 53.2-81.4%). Eleven of the 45 patients (24.4%, 95% CI 13.4-39.9%) were not receiving an agent with activity against their pathogen following Gram stain result availability (6 patients with MRSA and 5 with MSSA BSI).

**Days of therapy potentially saved**

In the 178 patients with known antibiotic history, at least 32 days of exposure to a broad spectrum beta-lactam (beta-lactam-beta-lactamase inhibitor combination, extended-spectrum cephalosporin or carbapenem) could have been spared with earlier knowledge of the final result, equating to a reduction in broad spectrum beta-lactam use in 18.0% of the patients in this study (32/178, 95% CI 12.8-24.6%).

A further 5 days of vancomycin use could have been avoided, and 17 days of antibiotic therapy could have been spared for the other agents (Supplementary Table 5). This equates to a reduction of 0.3 antibiotic days per patient (95% CI, 0.2-0.4).

In total, at least 54 days of antibiotic therapy could have been spared in the 178 patients with GPCC on blood culture in this study.

**Discussion**

**Evaluation**
The Xpert MRSA/SA BC system reliably differentiated *S. aureus* from CoNS. The assay showed a high sensitivity and specificity, was easy to use and is potentially implementable in a South African setting, where Xpert modules are widely available as part of the national programme for diagnosis of tuberculosis.

Methicillin resistance was detected with 100% accuracy in *S. aureus*; the small MRSA sample size precludes firm conclusions. Methicillin resistance in *S. aureus* is chiefly mediated by meca at present, although mecc-mediated resistance has been reported in 0.004% of human isolates (6). The assay also performed well for MSSA BSI, showing 100% concordance with culture-based testing. The error rate of 1.7% is similar to previous reports (3,7) and is acceptable. Although this assay has not been rigorously tested for the detection of methicillin resistance in CoNS to date, the negative predictive value of 95.8% in this context may be useful in selected cases of potentially significant CoNS bloodstream infection.

We recommend conventional culture to be performed at least limitedly in parallel, for mixed cultures, as a backup in case of an unsuccessful Xpert result and for further antimicrobial susceptibility testing or surveillance. Genotype-phenotype mismatch, with the Xpert assay incorrectly reporting a susceptible methicillin result due to insertions in the SCCmecc-orfX junction region, has been reported in 3 *S. aureus* isolates from the United States (8), and misclassification of *S. aureus* as CoNS in 2 isolates from Australia (9). Studies investigating the prevalence of mutations that may affect the targets of this assay in a South African setting are needed to define the role of this assay more accurately.

**Potential impact of implementation**

To our knowledge, this is the largest study assessing the potential impact of this assay to date. The median time saving to final result with use of this assay was approximately 30 hours if the Xpert assay was performed immediately after microscopy, in line with previous estimates of a time saving of 24-48 hours (2,10). This crude estimate can be influenced by factors such as workflow. Antibiotic therapy was optimised on availability of final result in 68.9% with *S. aureus* BSI. This impact was most clearly demonstrated in patients with MRSA BSI, where more than 50% received anti-MRSA therapy only in response to the final culture result. A more modest impact could be seen for patients with MSSA BSI (approximately 21%); however, it must be noted that this is a conservative estimate as all beta-lactam agents were considered to have activity against MSSA in this analysis, although they may not be equally suitable for the treatment of MSSA BSI and some are associated with a higher odds of death (11).

More rapid administration of appropriate therapy can significantly impact mortality. In one study, the mean mortality rate was 59% for patients with MRSA BSI who were initially started on a semisynthetic penicillin, as opposed to 23-36% for patients initially started on vancomycin (12). The mean mortality rate was as low as 12% in patients empirically placed on a semisynthetic penicillin, who cultured MSSA (12). Future studies should specifically assess the clinical impact of Xpert on more appropriate *S. aureus* therapy.
We estimated a reduction in broad spectrum beta-lactam antibiotic use in 18.0% of the cohort where antibiotic history was available, with 54 days of antibiotic therapy saved. This translates to a modest reduction in antibiotic days of therapy of 0.3 days per patient. When combined with the benefits shown in optimising therapy for \textit{S. aureus} BSI infection, this may still be regarded as advantageous, particularly when considered with the consequences of unnecessary antibiotic prescription.

We initially expected this assay to be of most use in reducing antibiotic therapy in patients with CoNS, as has been reported previously (13), but this finding was not replicated. The vast majority of CoNS bloodstream isolates were regarded as being not clinically significant in this cohort, in keeping with the high rate of BC contamination in our setting (14). Clinicians thus disregarded this “contaminated” result and continued the empiric antibiotic regimen that had been commenced based on the initial clinical assessment. Decisions regarding antibiotics are also governed by other factors not measured here, such as the clinical response to antibiotic therapy and additional test results.

The potential benefits described must be weighed against the expense of the assay, including additional labour, infrastructure and consumable costs. The total cost of the test may be prohibitive in a resource-constrained setting such as our own.

Limitations to this study include that the \textit{S. aureus} BSI rate was only 25.1% of all blood cultures with Gram positive cocci in clusters, and that methicillin resistance was detected in 26.3% of all \textit{S. aureus}-containing blood cultures (similar to a contemporaneous study in our setting (27.1%) (15)); this resulted in modest absolute numbers of MSSA and MRSA BSI. This may confer a more moderate impact of test performance than would be seen in higher prevalence settings. CA-MRSA is also not common in our setting currently (16). Secondly, complete clinical records were not available for all patients, prohibiting case-by-case assessment of whether antibiotic changes occurred as a result of the microbiological results or the evolving clinical picture. Furthermore, clinician recall bias may have influenced these results. Thirdly, other patient comorbidities, such as renal failure, and severity of illness may have contributed to the choice of agents used and the decision to modify antibiotic therapy; this could not be easily assessed. Fourthly, we sampled a proportion of those eligible for inclusion; although we compared these populations for all the key variables that would be available in a routine diagnostic laboratory setting (thereby limiting selection bias), other variables, such as source of sepsis, were not taken into account. Additionally, significant CoNS BSI may have been underestimated in this study, as clinicians in our setting infrequently adhere to recommendations for multiple blood cultures to be submitted in the investigation of sepsis. Finally, most beta-lactam agents were considered to have anti-MSSA activity for the purposes of this study, which may result in an underestimate of the clinical benefit of the assay for MSSA BSI.

\textbf{Conclusion}

The Xpert MRSA/SA BC assay performed well in differentiating \textit{S. aureus} from CoNS on positive blood cultures with Gram positive cocci in clusters and in detecting methicillin resistance in \textit{S. aureus}, and the
assay may be an effective antimicrobial stewardship tool. Further studies may need to be performed in areas with differing blood culture contamination and MRSA rates. We demonstrated potential benefit in reducing time to appropriate therapy in the majority of patients with \textit{S. aureus} bloodstream infection. Antibiotic modification based on the clinical response may have played a role in amplifying or attenuating the benefit observed in this study. We showed a modest reduction in antibiotics prescribed; studies limited to a more homogenous population may show a greater benefit. Additional studies assessing potential impact should focus on individual patient clinical status and outcomes, and should take into account source control, cost reduction in terms of antibiotic administration and hospital stay, and comprehensive costing.

**Abbreviations**

- BSI: bloodstream infection
- CA: community-acquired
- CI: confidence interval
- CoNS: coagulase-negative staphylococci
- GPCC: Gram positive cocci in clusters
- HA: hospital-acquired
- ICU: intensive care unit
- MRSA: methicillin-resistant \textit{Staphylococcus aureus}
- MSSA: methicillin-susceptible \textit{Staphylococcus aureus}
- Xpert: Xpert MRSA/SA BC

**Declarations**

**Ethics approval and consent to participate**

This study was performed in accordance with the Declaration of Helsinki. A waiver of individual informed consent was approved by the Human Health Research Ethics Committee (HREC) of Stellenbosch University, reference S14/10/201.

**Consent for publication**

Not applicable.

**Availability of data and materials**
The anonymised datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have neither financial nor non-financial competing interests.

**Funding**

Funding for this study was provided by the NHLS Research Trust, and we received cartridge donations and a loan instrument placement from Cepheid. The funders/donors had no role in the design, conduct and reporting of this study, and were not involved in the decision to publish the results of this study.

**Authors’ contributions**

KR collected and analysed the data, and wrote the manuscript. AW conceptualised and designed the study, guided data analysis and interpretation, and critically reviewed the manuscript. Both authors have approved the manuscript submitted to BMC Infectious Diseases.

**Acknowledgements**

The authors would like to thank the clinical staff and patients for participating in this study. We would also like to thank NHLS Tygerberg for the support, and Cepheid for donation of cartridges and placement of a loan instrument. Associate Professor Angela Dramowski reviewed the manuscript in a previous format and provided advice on improvements.

**Funding**

This project was funded by the NHLS Research Trust. Xpert MRSA/SA BC assays were donated by Cepheid.

**References**

1. Del Rio A, Cervera C, Moreno AN, Moreillon P, Miró JM. Patients at Risk of Complications of Staphylococcus aureus Bloodstream Infection. Clin Infect Dis. 2009;48:S246–53.

2. Yossepowitch O, Dan M, Kutchinsky A, Gottesman T, Schwartz-Harari O. A cost-saving algorithm for rapid diagnosis of Staphylococcus aureus and susceptibility to oxacillin directly from positive blood culture bottles by combined testing with BinaxNOW S. aureus and Xpert MRSA/SA assay. Diagn Microbiol Infect Dis [Internet]. 2014;78(4):352–5. Available from: http://dx.doi.org/10.1016/j.diagmicrobio.2014.01.001

3. Buchan BW, Allen S, Burnham CD, Tekippe EM, Davis T, Levi M, et al. Comparison of the next-generation Xpert MRSA/SA BC assay and the GeneOhm StaphSR assay to routine culture for
identification of Staphylococcus aureus and methicillin-resistant S. aureus in positive-blood-culture broths. J Clin Microbiol. 2015;53(3):804–9.

4. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes J. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128–40.

5. CLSI supplement M100S. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.

6. Diaz R, Ramalheira E, Afreixo V, Gago B. Methicillin-resistant Staphylococcus aureus carrying the new mecC gene — a meta-analysis. Diagn Microbiol Infect Dis. 2016;84:135–40.

7. Kelley PG, Grabsch EA, Farrell J, Xie S, Montgomery J, Mayall B, et al. Evaluation of the Xpert MRSA/SA Blood Culture assay for the detection of Staphylococcus aureus including strains with reduced vancomycin susceptibility from blood culture specimens. Diagn Microbiol Infect Dis [Internet]. 2011;70:404–7. Available from: http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.006

8. Tenover FC, Tickler IA, Le VM, Dewell S, Mendes RE, Goering R V. Updating molecular diagnostics for detecting methicillin- susceptible and methicillin-resistant Staphylococcus aureus Isolates in Blood Culture Bottles. J Clin Microbiol. 2019;57(11):1–11.

9. Lee G, Pang S, Coombs W. Misidentification of Staphylococcus aureus by the Cepheid Xpert MRSA/SA BC Assay Due to Deletions in the spa Gene. J Clin Microbiol. 2018;56(7):1–2.

10. Spencer DH, Sellenriek P, Burnham CD. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting. Am J Clin Pathol. 2011;(136):690–4.

11. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect [Internet]. 2011;17(10):1581–6. Available from: http://dx.doi.org/10.1111/j.1469-0691.2010.03425.x

12. Brown J, Paladino JA. Impact of Rapid Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Testing on Mortality and Cost Effectiveness in Hospitalized Patients with Bacteraemia. Pharmacoeconomics. 2010;28(7):567–75.

13. Parta M, Goebel M, Thomas J, Matloobi M, Stager C, Musher DM, et al. Impact of an Assay That Enables Rapid Determination of Staphylococcus Species and Their Drug Susceptibility on the Treatment of Patients with Positive Blood Culture Results. Infect Control Hosp Epidemiol. 2010;31(10):1043–8.

14. Abrahams MS, Whitelaw AC, Orth H. Time for a culture change? Suboptimal compliance with blood culture standards at a district hospital in Cape Town. South African Med J. 2015;105(12):1039–43.

15. Abdulgader SM, van Rijswijk A, Whitelaw A, Newton-Foot M. The association between pathogen factors and clinical outcomes in patients with Staphylococcus aureus bacteraemia in a tertiary hospital, Cape Town. Int J Infect Dis [Internet]. 2020;91:111–8. Available from: https://doi.org/10.1016/j.ijid.2019.11.032

16. Perovic O, Govender NP, Kularatne R, Whitelaw A, Chibabhai V, Naicker P, et al. A small proportion of community-associated methicillin-resistant Staphylococcus aureus bacteraemia, compared to
healthcare-associated cases, in two South African provinces. Eur J Clin Microbiol Infect Dis. 2017;Published online, 28 August 2017.

Tables

Table 1: Processing result interpretation of positive blood cultures containing Gram positive cocci in clusters

| Culture-based methods | Xpert MRSA/SA BC |
|------------------------|------------------|
|                        | Species identification | Methicillin susceptibility determination | Species identification | Methicillin susceptibility determination |
| **Methicillin-resistant *Staphylococcus aureus*** | DNAse and MSA positive; OR DNAse and MSA discrepant<sup>a</sup> AND *S. aureus* on VITEK 2 | Cefoxitin resistance on disk diffusion testing<sup>b</sup> | Detection of *spa* gene | Detection of *mecA* and the SCC*mec*-orfX region |
| **Methicillin-susceptible *Staphylococcus aureus*** | DNAse and MSA positive; OR DNAse and MSA discrepant<sup>a</sup> AND *S. aureus* on VITEK 2 | Cefoxitin susceptible on disk diffusion testing<sup>b</sup> | Detection of *spa* gene | Absence of *mecA* |
| **Coagulase-negative staphylococci*** | DNAse and MSA negative; OR DNAse and MSA discrepant AND no agglutination using Pastorex Staph Plus; OR CoNS species on VITEK 2 | Cefoxitin disk diffusion testing<sup>b</sup> | Absence of *spa* gene | Presence of *mecA* |

DNAse: Deoxyribonuclease; MSA: Mannitol Salt Agar; CoNS: coagulase-negative staphylococcus

<sup>a</sup>Pastorex Staph Plus-tested isolates exhibiting agglutination were all subjected to VITEK 2 confirmation. Isolates with no agglutination were considered coagulase-negative staphylococci, or were subjected to VITEK 2 identification at the discretion of the clinical microbiologist

<sup>b</sup>Cefoxitin category determined by clinical breakpoints outlined in the Clinical and Laboratory Standards Institute M100 document (2016)

Table 2: BacT/Alert blood culture bottles included in the diagnostic evaluation of Xpert MRSA/SA BC

| Bottle Type | n (%) | 95% confidence interval |
|-------------|-------|------------------------|
| FA Plus     | 132 (57.1) | 50.5-63.6 |
| FN Plus     | 19 (8.2) | 5.2-12.7 |
| PF Plus     | 80 (34.6) | 28.6-41.2 |
| Total       | 231 | - |
Table 3: Antibiotic progression in patients with *Staphylococcus aureus* bloodstream infection with antibiotic history (n=45)

|                     | Methicillin-sensitive *S. aureus* (n=34) | Methicillin-resistant *S. aureus* (n=11) |
|---------------------|-----------------------------------------|-----------------------------------------|
|                     | Empiric Choice n (%) [95% CI]           | In response to Gram result n (%) [95% CI] | On culture result n (%) [95% CI] | Empiric choice n (%) [95% CI] | In response to Gram result n (%) [95% CI] | On culture result n (%) [95% CI] |
| Patients receiving an agent with activity against the organism isolated\(^a\) | 27 (79.4) [61.6-90.7] | 29 (85.3) [68.2-94.5] | 34 (100) [87.4-100] | 3 (27.3) [7.3-60.7%] | 5 (45.5) [18.1-75.4] | 11 (100.0) [67.9-100.0] |

\(^a\)Empiric cover for MSSA included any agent with anti-MSSA activity, including ceftriaxone/cefotaxime for MSSA, Empiric cover for MRSA consisted of vancomycin in our setting.

MRSA: methicillin-resistant *Staphylococcus aureus*, MSSA: methicillin-sensitive *Staphylococcus aureus*; CI: confidence interval

Figures
Empiric antibiotics in patients with GPCC on blood culture and adequate antibiotic history MSSA: methicillin-sensitive Staphylococcus aureus; GPCC: Gram positive cocci in clusters. Ceftriaxone/cefotaxime were included as MSSA-active beta-lactam agents when used empirically.

| Classifiable patients with adequate antibiotic history (n=178) | On Gram stain: 12/178 (6.7%) [95% CI 3.7-11.8%] | On culture result: 16/178 (9.0%) [95% CI 5.4-14.4%] |
|---------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Modification of antibiotics n (%) [95% CI] | On Gram stain: 1/178 (0.6%) [95% CI 0.0-3.6%] | On culture result: 31/178 (17.4%) [95% CI 12.3-24.0%] |
| De-escalation of antibiotics n (%) [95% CI] | On Gram stain: 165/178 (92.7%) [95% CI 87.5-95.9%] | On culture result: 131/178 (73.6%) [95% CI 65.4-79.8%] |
| No change to antibiotics n (%) [95% CI] | | |

**Figure 2**

Antibiotic progression at Gram stain availability and final culture result availability CI: confidence interval. a Modification: change from an ineffective to a more effective agent, or the addition of a semisynthetic penicillin (methicillin-susceptible S. aureus) or glycopeptide (methicillin-resistant S. aureus); b De-escalation: change to a narrower-spectrum, targeted antistaphylococcal agent, or cessation of some or all antibiotics.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1R2final.docx
- Additionalfile2R2final.docx
- Additionalfile3R2final.docx
- Additionalfile4R2final.docx
- Additionalfile5R2final.docx